19.08.202502:43:49UTC+00Shares in Hong Kong Fall for 4th Session

Hong Kong's stock market experienced a decline on Tuesday, with the index dropping 35 points or 0.14%, settling at 25,211. This downturn represents the fourth consecutive decrease in value, influenced by the softening of U.S. futures as market participants anticipated a significant central bank summit expected to offer insights into the future direction of U.S. interest rates. Investor confidence remained shaky due to escalating debt repayment concerns within the Hong Kong property sector, with bond maturities forecasted to increase by nearly 70% next year amidst declining sales figures. Technology and consumer stocks largely faced downturns as market observers awaited the People's Bank of China's monthly review of the loan prime rate scheduled for Wednesday. The central bank's latest quarterly report underscored plans for targeted economic support, hinting at a restrained approach to major easing measures, despite July being the weakest month for China's economy so far this year. Potential market stability was afforded by reduced geopolitical strain following President Trump's suggestion of a meeting between Putin and Zelensky. Ascletis Pharma's shares plummeted by 12% following a discounted share sale, with other pharmaceutical companies underperforming, including Sino Biopharma (-4.9%), Wuxi Biologics (-4.4%), CSPC (-3.3%), and Innovent (-2.5%).